Estro has developed a patented solution to improve Fish Health for Norwegian and International Fish farms, the "SeaNest" solution reduce mortality, and facilitate and improve the working environment for both farmer and Fish. A controllable solution for the clean Fish in the Battle against the lice, zero contamination, and no loose parts eliminate the risk of pollution. Easy to Wash and handle. We have signed a full-scale test program with some of the largest companies within the business, and so far with a positive result. First Emission fulfilled mid of 2018, and the commercialization process started.

24Nettbutikk is one of the leading e-commerce platforms in the Norwegian market. More than 1200 small and medium businesses currently use the platform to sell their products through digital channels. 24Nettbutikk focuses on developing strong partnerships and technical integrations with leading providers of services such as logistics, payments and marketing to offer a complete solution for our merchants at a competitive cost. We have a strong focus on our customer's success and work hard every day to ensure that customers experience a short time to value and continuous growth in sales volume.

Nutcracker Solutions owns the product StadiaPitch by Bosch Rexroth and have licensed it to Bosch Rexroth until 2038.  The product is sold worldwide by the Bosch Corporation, and Nutcracker is a part of Bosch`s International StadiaPItch sales team. The goal is to reach 4 sales a year. Bosch pays Nutcracker a license fee between €1M - €1.5M per sale. 90% of the fee is due 5 months after Bosch has signed the contract with the stadium. Nutcracker has a flat predictable annual operating cost of €0.4M, regardless of how many StadiaPitch Sales Bosch Rexroth has in that year.  StadiaPitch entered the commercial phase in 2018 and has received an overwhelming market response. StadiaPitch is today included in the architectural drawings on three stadium projects, and Bosch has solid interest from several of the largest clubs in the world. StadiaPitch has received interest from architects, stadiums, and other stakeholders from 25 countries in the last 12 months.  Nutcracker is a dividend stock and the company is priced at 40 MNOK – pre-money. Nutcracker runs a Private Placement of 1OMNOK through a share issue that will equal to 20% of the new total number of shares. This funding will be spent on IPR, activities that enhance Bosch`s global sales work, and operating costs until we get income from the first Bosch contract. We pay a preference dividend equivalent to 50% of the investment for new investors. We have a commitment of 9 MNOK and we close the placement when we reach after the NXT 2019 events.

CoreAll is developing game-changing core drilling technology for the E&P industry. The Intelligent Coring System includes real-time coring process control with true formation evaluation data and the ability to core and drill with the same bottom hole assembly. The system has been patented in multiple countries. The development of the main system has successfully been completed with support from Lundin Norway, Spirit Energy, DEA, The Research Council of Norway and Innovation Norway. The system has completed four successful field tests in test wells and is ready for commercial introduction. CoreAll is seeking investors to finance the commercial operations capability. CoreAll was one of only two SME winners of the prestigious Spotlight on Technology award at the OTC in Houston in May 2018.

We digitize our customers by supporting more business processes with software. The core drivers are better insight and higher consistency. We make use of or create new software that solve each prospect. We are profitable and are looking to expand our offering with a modern platform. Voit offers IT systems that make less use of data with experience from everyday life, production and startups.

Biozep is discovering and developing first-in-class drug products for the treatment of severe eye diseases which can lead to vision loss and where it is a high unmet medical need. Biozep has discovered novel drug substances based on bioactive lipids which modulate central pathways involved in the pathogenesis of eye diseases. Targets and biomarkers are identified based on a system biology approach combined with in-depth knowledge about bioactive lipids, their endogenous synthesis and mechanisms of action. Biozep has made a prototype drug product based on our lead compound for topical administration and the product will be tested in animal models in 2018. Our goal is to start clinical studies in 2020. Biozep is a company depending on both internal and external resources. Biozep has established its own laboratory in Oslo in order to do synthesis, purification, quality control and chemical development in-house. The biological testing of the drug substances is performed in collaboration with carefully selected contract research organizations both in Europe and the USA. In order to reach the market as fast as possible and to reduce risk, Biozep will seek strategic partnerships early in the drug development phase. Biozep seeks partners with complementary competence and with resources to conduct clinical trials and with market access. We are already in dialogue with potential partners and hope to sign an agreement in 2018-19.

An intracellular approach to diagnostics – changing the way diagnostics approach blood tests. Pre Diagnostics is the first diagnostics company to focus on intracellular measurements of disease-specific biomarkers inside the blood cells. We extract disease-relevant information from biomarkers located inside specific blood cells called monocytes to provide actionable results for patients and practitioners.

"Lifeboats have killed more people than they have saved!" The statement is as far as I know unsupported, but widely known within the market of lifesaving equipment. Regulatory development, or rather a lack of such, has created a worldwide situation where lifesaving equipment on ships, ferries, cruise liners, you name it, have been torn between manufacturers, owners, service providers, and class and flag authorities, where all parties are biased by their commercial interest and their hopefully unconscious gamble that such equipment never has to be used. Not on their vessel. Not on my watch. The gamble is made with human lives at stake, and unfortunately, the odds are already written in blood. My system is based on my almost 20 years in this busyness. I have been a sailor who has trusted my own life on such equipment. I have been fortunate enough to use such equipment to save others. I have been responsible for the maintenance of such, I have worked with the leading manufacturers of such equipment as well as with companies providing service and inspections. I have also been part of the international organization responsible for the development of the rules for lifesaving equipment, and I have monitored this work closely for the last 10 years. I have seen all sides of the above-mentioned struggle. I know at the end of the day safety is at stake. I also have the solution. My system will benefit all parties and make equipment integrity and safety profitable for all. I am looking for a co-founder, CTO, and system developer to make my dream come true. I need someone with a passion to make a difference. Someone who values the thought of doing something nobody has done before, and who is willing to be in it for the long haul. I am sincerely looking forward to meeting you!

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

Preventing One Million Falls Before 2024 Dele Health Tech is redefining how the market conceptualizes and achieves fall prevention by offering a data fusion platform that functions as middleware between hardware and data stream partners. Our mission: To save lives through fall prevention, and prevent one million falls by 2024.

Gruten is an Oslo-based company that creates new value and meaning from coffee waste. We use coffee grounds in the production of soap and body scrub, and run an educational program with lectures, courses, and workshops to create awareness and knowledge about coffee grounds as a valuable resource.  We have a small production/workshop/outlet at Torshov, and sell our products on our own webshop + in ca 35 stores around Oslo and the rest of Norway. At the moment we are working hard to set up a site for mushroom production, growing oyster mushrooms on coffee grounds. When we get a go-ahead for this we will be in demand for funding to set up the production site (we will be growing in used cooling containers, so-called reefers) and need people to work on the site.

iTarget er et komplett mediehus som kan betjene både store, mellomstore og små bedrifter. Vi har lang og god erfaring fra å jobbe med noen av Norge’s største merkevarer, internasjonale kunder og mindre lokale bedrifter. Hos oss finner du både innholdsproduksjon, markedsstrategi, videoproduksjon, markedsføringstjenester, markedsavdeling for hire, animasjonsfilm, webdesign og mye mer. Det vi er bygget på og som er en stor del av det vi tilbyr våre kunder er langsiktig verdibasert markedsføring. Per i dag er vi 5 ansatte og betjener kunder over hele landet fra våre kontorer i Bergen.

Lima Regnskap AS er et autorisert regnskapsførerselskap som utfører alt innen regnskap, lønn, konsulentbistand, årsavslutning og har erfaring innen de fleste bransjer. Videre bistår vi gjerne med oppstart og registrering av nye virksomheter. Regnskapsfirmaet startet opp 1 juli 2017. Kontoret har en sentral beliggenhet på Ålgård.

- an easy-to-use all-in-one solution for the HORECA industry- GastroPlanner is one of Norway's leading suppliers of online tools for HORECA (hotels, restaurants, and catering). We offer a complete platform with all the tools and integrations needed to improve and streamline the daily operation of a HORECA business.

"Sammen om en jobb" (Together for a Job) is a Norwegian NGO running a mentor program between young immigrants and elderly Norwegians. The program has three principal aims:- transfer skills and knowledge from elderly people at the end of their professional careers to young immigrants just about to start theirs - provide a meaningful activity for people entering into retirement- support young immigrants in their job search- create relationships between different generations and cultures